

UNITED STATES OF AMERICA
Before the
SECURITIES and EXCHANGE COMMISSION

In The Matter Of

Release No. 34-88802

CNS Pharmaceuticals, Inc.

John M. Climaco

Petitioners,

NOTICE OF WITHDRAWAL OF
PETITION FOR TERMINATION OF
SUSPENSION OF TRADING IN THE
SECURITIES OF CNS
PHARMACEUTICALS, INC.

WHEREAS, on May 8, 2020, CNS Pharmaceuticals, Inc. (hereinafter "CNSP"), and John M. Climaco, in his capacity as Chairman and CEO of CNSP, filed a Petition for Termination of Suspension of Trading of Securities (hereinafter "Petition"), pursuant to Rule 550 of the Securities and Exchange Commission Rules of Practice, *Summary Suspensions Pursuant to Exchange Act Section 12(k)(1)(A)*, in connection with the temporary suspension of CNSP's securities (Release No. 34-88802) (hereinafter "Suspension Order"); and

WHEREAS, at 11:59 p.m. EDT on May 15, 2020 the Suspension Order that was the subject of the Petition terminated.

THEREFORE, Petitioners respectfully withdraw the Petition as moot.

Respectfully submitted,



By: _____

Cavas Pavri
Schiff Hardin LLP
100 N. 18th Street
Suite 300
Philadelphia, PA 19103
Counsel to CNS Pharmaceuticals, Inc.

CERTIFICATE OF SERVICE

I, **HEREBY CERTIFY** that a true and correct copy of the foregoing was filed on May 29, 2020 by electronic delivery to apfilings@sec.gov.

Pursuant to Release No. 34-88802, dated May 1, 2020, Petitioners and Petitioners' legal counsel, Cavas Pavri, agree to waive all paper service of all opinions and orders, and agree to accept service of all opinions and orders by email delivery. Their email addresses are: jclimaco@cnspharma.com and cpavri@schiffhardin.com.



By:

Cavas S. Pavri
Texas Bar No. 24002738